TrialJAMA cardiology2026

Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial.

Prem Soman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.